A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance by unknown
Engeholm et al. BMC Neurology 2014, 14:118
http://www.biomedcentral.com/1471-2377/14/118
CASE REPORT Open Access
A novel mutation in LRSAM1 causes axonal
Charcot-Marie-Tooth disease with dominant
inheritance
Maik Engeholm1,2*, Julia Sekler1,2, David C Schöndorf1,2,3, Vineet Arora1,2,3, Jens Schittenhelm4,
Saskia Biskup1,5, Caroline Schell1 and Thomas Gasser1,2
Abstract
Background: Charcot-Marie-Tooth disease (CMT) refers to a heterogeneous group of genetic motor and sensory
neuropathies. According to the primary site of damage, a distinction is made between demyelinating and axonal
forms (CMT1 and 2, respectively, when inherited as an autosomal dominant trait). Leucine-rich repeat and sterile alpha
motif-containing protein 1 (LRSAM1) is a ubiquitin-protein ligase with a role in sorting internalised cell-surface
receptor proteins. So far, mutations in the LRSAM1 gene have been shown to cause axonal CMT in three different
families and can confer either dominant or recessive transmission of the disease.
Case presentation: We have identified a novel mutation in LRSAM1 in a small family with dominant axonal CMT.
Electrophysiological studies show evidence of a sensory axonal neuropathy and are interesting in so far as giant motor
unit action potentials (MUAPs) are present on needle electromyography (EMG), while motor nerve conduction studies
including compound motor action potential (CMAP) amplitudes are completely normal. The underlying mutation
c.2046+1G>T results in the loss of a splice donor site and the inclusion of 63 additional base pairs of intronic DNA into
the aberrantly spliced transcript. This disrupts the catalytically active RING (Really Interesting New Gene) domain of
LRSAM1.
Conclusions: Our findings suggest that, beyond the typical length-dependent degeneration of motor axons,
damage of cell bodies in the anterior horn might play a role in LRSAM1-associated neuropathies. Moreover, in
conjunction with other data in the literature, our results support a model, by which disruption of the C-terminal RING
domain confers dominant negative properties to LRSAM1.
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Background
CMT comprises a clinically and genetically heterogeneous
group of inherited motor and sensory neuropathies [1].
With an overall prevalence of approximately 1 in 2,500
individuals, CMT is the most common genetic disorder of
the PNS [2]. In a majority of cases, CMT is transmitted
as an autosomal dominant trait and is further classified as
CMT1 or CMT2 according to the primary site of damage
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(demyelinating and axonal, respectively) [1,3]. In other
families, CMT is transmitted as an X-linked or autosomal
recessive trait. These latter cases are commonly classified
as CMT4 when they show a demyelinating phenotype,
while axonal forms are referred to as autosomal reces-
sive CMT2 (AR-CMT2) [4]. Since the identification of a
duplication of the peripheral myelin protein 22 locus as
the cause of CMT1A more than 20 years ago [5,6], muta-
tions in more than 60 genes implicated in a variety of
different cellular functions have been associated with var-
ious forms of CMT [3]. Beyond their relevance for clinical
classification, these genes identify molecules and molec-
ular pathways that play a primary role for the structural
and functional integrity of PNS neurons and their myelin
© 2014 Engeholm et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
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sheath, respectively, and are potential targets for future
therapeutic interventions.
Three different mutations in the LRSAM1 gene have
been shown to cause axonal CMT in humans. Guernsey
et al. [7] reported a large, multiply consanguineous family
from Eastern Canada, in which axonal CMTwas inherited
as an autosomal recessive trait. The clinical presentation
included moderate weakness and wasting, predominantly
affecting distal lower limb muscles, with an onset in
early adulthood. Needle EMG revealed signs of den-
ervation and reinnervation, and sensory nerve action
potentials (SNAPs) were reduced or absent. Homozygos-
ity mapping yielded a splice site mutation c.1913-1G>A
in the LRSAM1 gene giving rise to a premature stop
codon 20 bp inside the penultimate exon. Subsequently,
two further mutations in LRSAM1 were identified in
a Dutch and a Sardinian family with dominant axonal
CMT [8,9]. In both studies, the clinical and electrophys-
iological findings were very similar to that reported by
Guernsey et al. [7]. Both mutations, p.Leu708ArgfsX28
and p.Ala683ProfsX3, disrupt the RING domain
of LRSAM1.
LRSAM1 is a E3 ubiquitin-protein ligase highly con-
served throughout vertebrate evolution [10]. Alternative
splicing gives rise to three different isoforms in humans,
the largest of which consists of 723 amino acids and har-
bours anN-terminal leucine-rich repeat domain, an ezrin-
radixin-moezin domain, a coiled-coil region, a sterile
alpha motif domain and a C-terminal C3HC4-type RING
finger domain (Figure 1e). In human andmouse, LRSAM1
is highly expressed in motor neurons of the spinal cord
and cell bodies of sensory neurons of dorsal root gan-
glia [8,11]. Moreover, some expression is observed in the
central nervous system [10,11]. In a cell culture system,
LRSAM1 has been shown to interact with and medi-
ate monoubiquitination of the Tumour susceptibility gene
101 protein (TSG101) [10]. TSG101 is a component of
the ESCRT (Endosomal Sorting Complexes Required for
Transport)-1 complex, which is involved in the sorting
of endocytic ubiquitinated cargoes into lumenal vesicles
of late endosomes [12]. Upon LRSAM1-mediated ubiq-
uitination, TSG101 relocalises from these multivesicular
bodies to a detergent-soluble compartment and loses its
ability to direct internalised receptor proteins to the lyso-
some [10]. In a mouse model, loss of LRSAM1 results in
decreased motor NCVs and motor axon counts follow-
ing acrylamide challenge, while neuromuscular function
is otherwise unimpaired [11].
Here, we report a novel mutation in LRSAM1 in a
small family with autosomal dominant axonal CMT. We
present an in-depth electrophysiological examination of
three affected individuals and characterise the functional
consequences of the splice site mutation at the level of
the transcript. Our results provide new insights into the
pathomechanism of LRSAM1-associated neuropathies,
both at the cellular and molecular level.
Case presentation
We present a family with three members suffering
from a predominantly sensory neuropathy with fascic-
ulations and hyper-CK-aemia but without evidence of
motor axonal neuropathy in nerve conduction studies
(Figure 1a). The 47-years old index patient complained
of a reduced sensation for touch on his feet, for instance
when trying on shoes, which he had first noticed more
than 20 years ago. Over the past few years, these deficits
had gradually spread over his lower legs and recently also
reached his finger tips. For several years he had noticed an
unsteady gait, especially when walking in the dark, and he
reported long-standing fasciculations of his calf and thigh
muscles as well as crampi affecting both the leg and hand
muscles. Over the past year, he had observed a reduction
in size of his calf muscles. He did not complain of weak-
ness, paresthesias or vegetative symptoms. His 43-years
old sister and his 69-years old mother had very similar
complaints with an age of onset between 20 and 40 years.
Clinical examination of the index patient showed fasci-
culations of proximal leg muscles. The intrinsic foot and
handmuscles appeared slender, but no other signs of atro-
phy or skeletal deformities were observed. There was no
motor weakness. Deep tendon reflexes were normal in
the upper extremities but absent in the lower extrem-
ities. Sensation for touch, vibration, heat and pain was
markedly reduced in the lower legs, and tandem gait was
mildly impaired. While clinical examination of the sis-
ter gave very similar results, in the mother an additional
grade 4/5 weakness of ankle dorsiflexion and intrinsic
hand muscles was present. Laboratory testing revealed a
moderate hyper-CK-aemia in all three individuals (maxi-
mum 480 U/l in the mother), while other parameters were
normal. Electrodiagnostic studies yielded similar findings
in all three individuals (Table 1). Firstly, sensory nerve
conduction studies showed reduced SNAPs in upper and
lower extremity nerves. Secondly, while there was no evi-
dence of acute denervation on needle examination, giant
MUAPs were observed both in proximal and distal mus-
cles. Thirdly, motor nerve conduction studies including
CMAPs were completely normal. A biopsy of the sural
nerve in the index patient showed a chronic neuropathy
with predominantly axonal damage (Figure 1b).
Genetic testing was performed on the index patient
by means of whole exome sequencing. Data analysis was
confined to a group of 46 candidate genes, which had
previously been associated with CMT (a complete list is
available on request). Only variants in these genes that
had an allele frequency of less than 0.05 and could not
be classified as benign based on current knowledge were
considered further. This revealed a single heterozygous
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Figure 1 Pedigree, biopsy andmolecular biology studies. a) Pedigree of the family. The index patient is individual III.3. b) Tolouidine
blue-stained semi-thin section of a sural nerve biopsy from the index patient. Shown are several small clusters of axons as an indication of axonal
regeneration (red arrows) and one axon undergoing acute Wallerian degeneration (black arrow). The overall number of axons is slightly reduced.
c) RT-PCR amplification of LRSAM1 mRNA from blood of the index patient (lane 1) and a healthy control patient (lane 2). d) Sanger sequencing of
the PCR product from c. Shown is a sequence alignment of the wild type sequence (top) and the sequence obtained from the larger size PCR
product in the index patient (bottom and chromatogram). e) LRSAM1 domain structure and sites of disease causing mutations. LRR - leucine rich
repeat domain; ERM - ezrin-radixin-moezin domain; CC - coiled coil region; SAM - sterile alpha motif domain; PTAB - PTAB motif domain; RING - RING
finger domain. Positions are indicated by amino acid number. The recessive mutation from Guernsey et al. is highlighted blue, dominant mutations


















Table 1 Electrophysiological studies
Index Sister Mother
Nerve CMAP/mV mNCV/ms−1 CMAP/mV mNCV/ms−1 CMAP/mV mNCV/ms−1
N. ulnaris [4.0 mV / 50 ms−1] 23 68 19 61 15 57
N. tibialis [5.0 mV / 40 ms−1] 11 51 24 51 6.4 40
N. peronaeus [4.0 mV / 41 ms−1] 9.9 47 n.d. n.d. n.d. n.d.
Index Sister Mother
Nerve SNAP/μV sNCV/ms−1 SNAP/μV sNCV/ms−1 SNAP/μV sNCV/ms−1
N. radialis [16 μV / 55 ms−1] 8.8 67 15 55 6.1 58
N. suralis [3.8 μV / 39 ms−1] 1.6 50 2.7 43 Ø n.a.
Index Sister Mother
Muscle ASA MUAP/mV ASA MUAP/mV ASA MUAP/mV
M. deltoideus [1.5 mV] Ø 2.0 Ø 2.7 Ø 6.4
M. IOD1 [2.3 mV] Ø 7.5 n.d. n.d. Ø 12
M. vastus medialis [2.0 mV] Ø 16 Ø 28 Ø 28
M. tibialis anterior [1.6 mV] Ø 4.3 n.d. n.d. n.d. n.d.
Motor nerve conduction studies, sensory nerve conduction studies and needle EMG recorded from the index patient (index), his sister and his mother. CMAP - compound motor action potential; mNCV - motor nerve
conduction velocity; SNAP - sensory nerve action potential; sNCV - sensory nerve conduction velocity; M. IOD1 - musculus interosseus dorsalis 1; ASA - abnormal spontaneous activity (fibrillation potentials or positive sharp
waves); Ø - not present; n.d. - not determined; n.a. - not applicable. Normal ranges for CMAP, SNAP and MUAP amplitudes as well as NCVs are indicated in brackets in column 1. Pathological results are highlighted bold.
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mutation in LRSAM1 c.2046+1G>T, which could be con-
firmed by Sanger sequencing and was also present in the
sister and mother. Other family members were not avail-
able for testing. The mutation destroys the splice donor
site downstream of exon 25. To test if the mutant allele is
expressed and to map the alternative splice donor site, RT-
PCR was performed on RNA isolated from blood using
primers located in exon 23 and 26 (LRSAM1_c2424_fw:
acctgctgagccaaatgagc and LRSAM1_c2803_rv: tcagctgct
gtggtagatgc). In a healthy control subject, this yielded a
single product of 443 bp, as expected. In the index patient,
however, a second slightly larger band was observed
(Figure 1c). Sanger sequencing showed that this second
band corresponds to an aberrantly spliced LRSAM1 tran-
script from themutant allele, in which an alternative splice
donor site 63 bp downstream of the mutated site is used
(Figure 1d). This results in the insertion of 21 additional
amino acids into the LRSAM1 protein leading to a dis-
ruption of the RING domain (Figure 1e and Table 2). This
mutation is predicted to be deleterious by PROVEAN [13]
with high confidence (PROVEAN score of -19.2).
Conclusions
We report a small family with autosomal dominant axonal
CMT associated with a novel mutation in LRSAM1. In the
affected individuals sensory deficits including impaired
sensation of touch and disturbed proprioception dom-
inate the clinical picture. Motor symptoms are present
as well but are limited to fasciculations and crampi in
the younger two individuals, while only the 70-years
old mother showed distal predominant weakness. The
onset of symptoms was reported between the second and
fourth decade in all individuals, and the clinical course
is relatively mild and benign. The underlying mutation
in the LRSAM1 gene destroys the splice donor site at
the 3’-end of exon 25. Instead, an alternative splice site
63 bp further downstream is used. This results in the
insertion of 21 amino acids into the RING domain of
LRSAM1 most likely rendering this domain catalytically
inactive (Table 2). All in all, the clinical features present
in our patients are very similar to those reported for the
three other families. CMT associated with mutations in
LRSAM1 is now referred to as CMT2P, irrespective of its
(dominant or recessive) mode of inheritance [1,3].
We have observed rather distinctive electrodiagnos-
tic findings in our family, which in some respect differ
from those generally reported in patients with axonal
CMT. Despite clear motor involvement on clinical and
laboratory examination, including distal predominant
weakness in the mother and fasciculations and crampi
in all three individuals, motor nerve conduction stud-
ies (including CMAP amplitudes) were entirely normal
(Table 1). At the same time, needle EMG showed giant
MUAPs both in proximal and distal muscles of all indi-
viduals. Such giant potentials are frequently observed
in slowly progressive forms of anterior horn cell dis-
ease. The finding might be taken as an indication that
in the patients reported here cellular damage affects
not only the axon in a typical length-dependent man-
ner but also the cell body of the lower motor neuron.
Consistent with this idea, denervation of paraspinal mus-
cles has been documented in one family with LRSAM1-
associated CMT [7]. The normal CMAP amplitudes,
similar to giant MUAPs, may be considered the result
of extensive axonal regeneration in LRSAM1-associated
neuropathies. However, all in all, further detailed reports
of electrophysiological and histopathological findings in
genetically defined neuropathies are needed to address
the question of how well this type of study can pro-
vide information regarding the subcellular site of dam-
age or the kinetics of degenerative and regenerative
processes.
An interesting feature of LRSAM1 is that different
mutations in the same gene cause either recessive or
dominant forms of CMT. A similar behaviour has been
observed for a number of other disease-associated genes,
and the underlying molecular mechanisms are subject of
intensive research [14-17]. In the case of LRSAM1, the
mutation described by Guernsey et al. [7] is likely to be
a null mutation due to a stop codon in the penultimate
exon of the aberrantly spliced transcript. The stop codon
is normally found within the very last exon of a gene,
and its premature occurrence in any other exon can trig-
ger degradation of the mRNA by a mechanism referred
to as nonsense-mediated decay [18]. Consistent with this
notion, Guernsey et al. [7] have failed to detect LRSAM1
protein in blood cells of homozygous mutation carriers
(Table 2).
Table 2 Comparison of LRSAM1mutations
DNA Protein Expression RING domain Transmission Reference
c.1913-1G>A p.Glu638AlafsX7 Ø n.a. Recessive Guernsey et al. 2010 [7]
c.2122_2123insGC p.Leu708ArgfsX28 n.d. Disrupted Dominant Weterman et al. 2012 [8]
c.2047-1G>A p.Ala683ProfsX3 + Disrupted Dominant Nicolaou et al. 2013 [9]
c.2046+1G>T p.Glu682_Ala683ins21 n.d. Disrupted Dominant Herein
Overview of mutations in LRSAM1 associated with axonal CMT. Expression refers to protein expression as determined by Western blotting in whole-cell lysates of
patient-derived lymphoblastoid cell lines. The RING domain (amino acid 675-710) is called disrupted when not present in its entirety.
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The absence of clinical symptoms in heterozygous car-
riers of the null mutation described by Guernsey et al.
[7] suggests that the other three mutations reported by
Weterman et al. [8], Nicolaou et al. [9] and herein exert
a dominant negative effect, rather than lead to haploin-
sufficiency. Consistent with this idea, the mutant protein
could be detected in blood cells of heterozygous muta-
tion carriers in one family [9]. It is tempting to speculate
that such a dominant negative effect results immediately
from the disruption of the RING domain, where all three
mutations occur (Table 2). Artificially engineered muta-
tions inactivating the RING domain of LRSAM1 not only
fail to confer ubiquitination, but at the same time show an
increased physical association with the substrate TSG101
[10]. This appears to reinforce the endosomal localisa-
tion of TSG101 and enhance its sorting activity, possibly
through blocking its ubiquitination by wild-type LRSAM1
or other ubiquitin ligases. It is conceivable that a similar
type of blocking interaction occurs between catalytically
inactive mutants of LRSAM1 and other physiological sub-
strates.
Further studies are needed to investigate if the misregu-
lation of ESCRT complexes in LRSAM1 mutation carriers
is responsible for the CMT phenotype or if other yet
unknown functions of LRSAM1 also play a role. In this
context, it is worthmentioning that the product of another
CMT2-associated gene, small integral membrane pro-
tein of lysosome/late endosome (SIMPLE), also interacts
with various components of ESCRT complexes including
TSG101 [19]. Note however, that in cell culture experi-
ments SIMPLE and LRSAM1 (as well as the respective
disease-associatedmutations) have opposite effects on the
function of ESCRT complexes: While SIMPLE promotes
the assembly of endosomal ESCRT complexes and thereby
accelerates lysosomal degradation of activated growth fac-
tor receptors, LRSAM1-dependent ubiquitination causes
the disassembly of these sorting complexes resulting in
prolonged signalling of the activated receptors [10,20]. It
is conceivable that a tightly controlled balance between
the two processes is a prerequisite for an optimal reg-
ulation of neurotrophic signalling in PNS neurons. The
use of patient-derived induced pluripotent stem cells [21],
which can be differentiated into motor neurons [22], will
offer the opportunity to study these processes in a more
authentic context than previous cell culture experiments.
Finally, our study illustrates the power of targeted
exome analyses as a diagnostic procedure especially for
patients with neurodegenerative disorders. As a first step,
the approach involves whole exome sequencing using
standard next-generation sequencing technologies. Sub-
sequent data analysis, however, is confined to genes that
have previously been associated with the clinically sus-
pected diagnosis. In our case, this group comprised 46
genes at the time of examination. In our experience,
this strategy is far more efficient than are conventional
sequencing panels or the successive sequencing of individ-
ual candidate genes, especially when dealing with genet-
ically diverse diseases such as CMT [1,3]. In addition, it
provides a high degree of flexibility, as it is possible to
re-assess the original exome data at a later stage in case
new genes are added to a list of candidate genes or new
symptoms appear in the course of a disease indicating a
different clinical diagnosis. Our case illustrates that by this
method it is possible to identify novel heterozygous dis-
ease causing mutations, as long as they occur within a
gene that belongs to a suitable group of candidate genes
defined by clinical considerations.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
Abbreviations
CMAP: Compound motor action potentials; CMT: Charcot-Marie-Tooth
disease; EMG: Electromyography; ESCRT: Endosomal sorting complexes
required for transport; LRSAM1: Leucine-rich repeat and sterile alpha
motif-containing protein 1; MUAP: Motor unit action potentials; NCV: Nerve
conduction velocities; PNS: Peripheral nervous system; RING: Really interesting
new gene; SIMPLE: Small integral membrane protein of lysosome/late
endosome; SNAP: Sensory nerve action potential; TSG101: Tumour
susceptibility gene 101 protein.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ME, CS, SB and TG saw the patient and diagnosed CMT; CS performed
electrophysiological studies; JSch performed histopathological studies; SB
performed exome sequencing; JS, DCS, VA, ME and TG performed molecular
biology studies. ME wrote the manuscript with contributions from all other
authors. All authors read and approved the final version of the manuscript.
Acknowledgements
The authors would like to acknowledge support by Deutsche
Forschungsgemeinschaft and Open Access Publishing Fund of Tübingen
University to cover publication costs of this article.
Author details
1Department of Neurology and Hertie Institute for Clinical Brain Research,
Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany. 2German Center for
Neurodegenerative Diseases (DZNE), Otfried-Müller-Str. 27, 72076 Tübingen,
Germany. 3Graduate School of Cellular & Molecular Neuroscience, Österbegstr.
3, 72074 Tübingen, Germany. 4Division of Neuropathology, Calwerstr. 3, 72076
Tübingen, Germany. 5CeGaT GmbH, Paul-Ehrlich-Str. 17, 72076 Tübingen,
Germany.
Received: 14 April 2014 Accepted: 30 May 2014
Published: 3 June 2014
References
1. Vallat J-M, Mathis S, Funalot B: The various charcot-marie-tooth
diseases. Curr Opin Neurol 2013, 26(5):473–480.
Engeholm et al. BMC Neurology 2014, 14:118 Page 7 of 7
http://www.biomedcentral.com/1471-2377/14/118
2. Braathen GJ, Sand JC, Lobato A, HÃÿyer H, Russell MB: Genetic
epidemiology of charcot-marie-tooth in the general population.
Eur J Neurol 2011, 18(1):39–48.
3. Rossor AM, Polke JM, Houlden H, Reilly MM: Clinical implications of
genetic advances in charcot-marie-tooth disease. Nat Rev Neurol
2013, 9(10):562–571.
4. Tazir M, Bellatache M, Nouioua S, Vallat J-M: Autosomal recessive
charcot-marie-tooth disease: from genes to phenotypes. J Peripher
Nerv Syst 2013, 18(2):113–129.
5. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask
BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, Chakravarti A,
Patel PI: Dna duplication associated with charcot-marie-tooth
disease type 1a. Cell 1991, 66(2):219–232.
6. Raeymaekers P, Timmerman V, Nelis E, Jonghe P. D, Hoogendijk JE, Baas F,
Barker DF, Martin JJ, Visser MD, Bolhuis PA: Duplication in chromosome
17p11.2 in charcot-marie-tooth neuropathy type 1a (cmt 1a). the
hmsn collaborative research group. Neuromuscul Disord 1991,
1(2):93–97.
7. Guernsey DL, Jiang H, Bedard K, Evans SC, Ferguson M, Matsuoka M,
Macgillivray C, Nightingale M, Perry S, Rideout AL, Orr A, Ludman M,
Skidmore DL, Benstead T, Samuels ME:Mutation in the gene encoding
ubiquitin ligase lrsam1 in patients with charcot-marie-tooth
disease. PLoS Genet 2010, 6(8):e1001081.
8. Weterman MAJ, Sorrentino V, Kasher PR, Jakobs ME, van Engelen BGM,
Fluiter K, de issel MB, Sizarov A, Nürnberg G, Nürnberg P, Zelcer N,
Schelhaas HJ, Baas F: A frameshift mutation in lrsam1 is responsible
for a dominant hereditary polyneuropathy. HumMol Genet 2012,
21(2):358–370.
9. Nicolaou P, Cianchetti C, Minaidou A, Marrosu G, Zamba-Papanicolaou E,
Middleton L, Christodoulou K: A novel lrsam1mutation is associated
with autosomal dominant axonal charcot-marie-tooth disease. Eur J
HumGenet 2013, 21(2):190–194.
10. Amit I, Yakir L, Katz M, Zwang Y, Marmor M. D, Citri A, Shtiegman K, Alroy I,
Tuvia S, Reiss Y, Roubini E, Cohen M, Wides R, Bacharach E, Schubert U,
Yarden Y: Tal, a tsg101-specific e3 ubiquitin ligase, regulates
receptor endocytosis and retrovirus budding. Genes Dev 2004,
18(14):1737–1752.
11. Bogdanik LP, Sleigh JN, Tian C, Samuels ME, Bedard K, Seburn KL, Burgess
RW: Loss of the e3 ubiquitin ligase lrsam1 sensitizes peripheral
axons to degeneration in a mouse model of charcot-marie-tooth
disease. Dis Model Mech 2013, 6(3):780–792.
12. Hurley JH: Escrt complexes and the biogenesis of multivesicular
bodies. Curr Opin Cell Biol 2008, 20(1):4–11.
13. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP: Predicting the functional
effect of amino acid substitutions and indels. PLoS One 2012,
7(10):46688.
14. Rees MI, Andrew M, Jawad S, Owen MJ: Evidence for recessive as well
as dominant forms of startle disease (hyperekplexia) caused by
mutations in the alpha 1 subunit of the inhibitory glycine receptor.
HumMol Genet 1994, 3(12):2175–2179.
15. Zhang J, George AL, Griggs RC, Fouad GT, Roberts J, Kwiecin´ski H,
Connolly AM, Ptácek LJ:Mutations in the human skeletal muscle
chloride channel gene (clcn1) associated with dominant and
recessive myotonia congenita. Neurology 1996, 47(4):993–998.
16. Barletta MRD, Ricci E, Galluzzi G, Tonali P, Mora M, Morandi L, Romorini A,
Voit T, Orstavik KH, Merlini L, Trevisan C, Biancalana V,
Housmanowa-Petrusewicz I, Bione S, Ricotti R, Schwartz K, Bonne G,
Toniolo D: Different mutations in the lmna gene cause autosomal
dominant and autosomal recessive emery-dreifuss muscular
dystrophy. Am J HumGenet 2000, 66(4):1407–1412.
17. Houlden H, Laura M, Vrièze FW-D, Blake J, Wood N, Reilly MM:Mutations
in the hsp27 (hspb1) gene cause dominant, recessive, and sporadic
distal hmn/cmt type 2. Neurology 2008, 71(21):1660–1668.
18. Kervestin S, Jacobson A: Nmd: a multifaceted response to premature
translational termination. Nat Rev Mol Cell Biol 2012, 13(11):700–712.
19. Shirk AJ, Anderson SK, Hashemi SH, Chance PF, Bennett CL: Simple
interacts with nedd4 and tsg101: evidence for a role in lysosomal
sorting and implications for charcot-marie-tooth disease. J Neurosci
Res 2005, 82(1):43–50.
20. Lee SM, Chin L-S, Li L: Charcot-marie-tooth disease-linked protein
simple functions with the escrt machinery in endosomal trafficking.
J Cell Biol 2012, 199(5):799–816.
21. Bellin M, Marchetto MC, Gage FH, Mummery CL: Induced pluripotent
stem cells: the new patient? Nat Rev Mol Cell Biol 2012, 13(11):713–726.
22. Ebert AD, Yu J, Rose FF, Mattis VB, Lorson CL, Thomson JA, Svendsen CN:
Induced pluripotent stem cells from a spinal muscular atrophy
patient. Nature 2009, 457(7227):277–280.
doi:10.1186/1471-2377-14-118
Cite this article as: Engeholm et al.: A novel mutation in LRSAM1 causes
axonal Charcot-Marie-Tooth disease with dominant inheritance.
BMC Neurology 2014 14:118.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
